

PRECEPTORSHIP PROGRAMME

Colorectal Cancer

**ESMO
PRECEPTORSHIP**

**VALENCIA SPAIN
19-20 MAY 2023**

Multidisciplinary management, standards
of care and future perspectives.

Co-Chairs

Andrés Cervantes, Spain
Erika Martinelli, Italy

ESMO PRECEPTORSHIP PROGRAMME COLORECTAL CANCER

Multidisciplinary management, standards of care
and future perspectives

Valencia, Spain
19-20 May 2023

CO-CHAIRS

Andrés Cervantes, Spain
Erika Martinelli, Italy

SPEAKERS

Dirk Arnold, Germany
Myriam Chalabi, Netherlands
Dimitri Dorcaratto, Spain
Michel Ducreux, France
Carolina Martínez-Ciarpaglini, Spain
Jenny Seligmann, United Kingdom

LEARNING OBJECTIVES

- To learn about best clinical practice in the multidisciplinary management of colorectal cancer in the adjuvant and metastatic settings
- To understand the importance of pathology, histo- and moleculopathological prognostic factors
- To learn about sequencing of treatments, adverse events and special situations

ACCREDITATION

The programme of this event has been accredited with **9 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4, 6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Friday, 19 May 2023

| | | |
|----------------------------|---|--|
| 09:00-09:15 15' | Welcome and introduction | Andrés Cervantes, ES Erika Martinelli, IT |
| 09:15-10:50 95' | SESSION 1 Localised colon cancer – Part 1 | Chair: Andrés Cervantes, ES |
| 30' | Quality and rules of a good pathology report Histo- and moleculopathological biomarkers | Carolina Martínez-Ciarpaglini, ES |
| 30' | Adjuvant treatment for colon cancer stage II and III as standard of care | Michel Ducreux, FR |
| 20' | Neoadjuvant chemotherapy for localised colon cancer as a potential option | Jenny Seligmann, UK |
| 15' | Q&A | Faculty |
| 10:50-11:20 | Coffee break | |
| 11:20-12:30 70' | SESSION 2 Localised colon cancer – Part 2 | Chair: Erika Martinelli, IT |
| 30' | Neoadjuvant immunotherapy for localised colorectal cancer: facts and future prospective | Myriam Chalabi, NL |
| 10' | Q&A | Faculty |
| 30' | Participants clinical case discussion (3x10') | Faculty |
| 12:30-13:30 | Lunch | |
| 13:30-15:05 95' | SESSION 3 Current first-line treatment for metastatic colorectal cancer | Chair: Andrés Cervantes, ES |
| 40' | Current treatment of metastatic colorectal cancer: basic strategies according to clinical and molecular subgroups "MSI-H" | Erika Martinelli, IT |
| 10' | Q&A | Faculty |
| 45' | Presentation of three challenging clinical cases by the expert and faculty discussion | Jenny Seligmann, UK Faculty |
| 15:05-15:35 | Coffee break | |
| 15:35-17:20 105' | SESSION 4 Metastatic colorectal cancer: Special clinical situations | Chair: Andrés Cervantes, ES |
| 30' | Oligometastatic colorectal cancer: What to know about it and how to treat it | Dirk Arnold, DE |
| 30' | How to integrate surgery in the treatment of patients with liver-only metastatic disease | Dimitri Dorcaratto, ES |
| 15' | Discussion | Faculty |
| 30' | Participants clinical case discussion (3x10') | Faculty |
| 20:30 | Dinner | |

Saturday, 20 May 2023

| | | |
|----------------------------|--|--|
| 09:00-10:45 105' | SESSION 5 Metastatic colorectal cancer: Maintenance and further lines | Chair: Andrés Cervantes, ES |
| 20' | What to do after first-line failure? | Jenny Seligmann, UK |
| 20' | Treating patients with chemorefractory disease: challenges and opportunities | Dirk Arnold, DE |
| 30' | Management of treatment-related side effects: <ul style="list-style-type: none"> - GI-toxicity - Neuropathy - Skin toxicity - Hypertension - Hand-foot syndrome | Michel Ducreux, FR |
| 20' | How to deal with patients with BRAF mutant and HER2 amplified advanced colorectal cancer after 1 st failure | Erika Martinelli, IT |
| 15' | Q&A | Faculty |
| 10:45-11:15 Coffee break | | |
| 11:15-11:55 40' | SESSION 6 Localized rectal cancer | Chair: Erika Martinelli, IT |
| 30' | Standard of care of localised rectal cancer | Andrés Cervantes, ES |
| 10' | Q&A | Faculty |
| 11:55-12:25 30' | SESSION 7 Metastatic colorectal cancer: Case discussion | Chair: Andrés Cervantes, ES |
| 30' | Participants clinical case discussion (3x10') | Faculty |
| 12:25-12:35 10' | Conclusion and farewell | Andrés Cervantes, ES Erika Martinelli, IT |
| 12:35-13:35 Lunch | | |

Note: Each 10-minute slot for clinical case discussion includes a 5' case presentation and a 5' Q&A / panel discussion